uniQure (NASDAQ:QURE) Given "Buy" Rating at HC Wainwright

uniQure (NASDAQ:QURE - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $70.00 price objective on the biotechnology company's stock. HC Wainwright's price objective would indicate a potential upside of 380.77% from the company's previous close.

Other research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a report on Saturday, May 24th. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price target on shares of uniQure in a report on Monday, May 12th. Wells Fargo & Company lowered their price target on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $38.00 price target on shares of uniQure in a report on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $37.82.

uniQure Price Performance

QURE stock traded down $0.34 during trading on Thursday, reaching $14.56. The company's stock had a trading volume of 1,712,177 shares, compared to its average volume of 1,908,946. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $797.54 million, a P/E ratio of -2.94 and a beta of 0.10. The company's fifty day moving average is $12.53 and its 200-day moving average is $12.91.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $5.93 million. On average, research analysts expect that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at $6,703,461.66. This trade represents a 4.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Christian Klemt sold 10,438 shares of uniQure stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $107,407.02. Following the transaction, the chief financial officer now directly owns 217,730 shares in the company, valued at approximately $2,240,441.70. The trade was a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 40,129 shares of company stock valued at $412,927. 4.74% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Several institutional investors have recently bought and sold shares of the business. Vestal Point Capital LP increased its holdings in uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after buying an additional 1,767,572 shares during the period. Nantahala Capital Management LLC increased its holdings in uniQure by 3.8% during the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock valued at $29,213,000 after buying an additional 101,598 shares during the period. Aberdeen Group plc increased its holdings in uniQure by 46.8% during the first quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock valued at $23,485,000 after buying an additional 706,216 shares during the period. Avoro Capital Advisors LLC purchased a new position in uniQure in the fourth quarter worth $38,410,000. Finally, Franklin Resources Inc. grew its holdings in uniQure by 33.1% in the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after purchasing an additional 494,726 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.